Institute Of Cancer Research, United Kingdom

This trial is testing new drug combinations for women whose gynecologic cancers (like ovarian or uterine cancer) have returned after previous treatment. It aims to see if matching specific drug combinations to a patient's cancer type and a particular gene change (called ARID1A) c…

This study is testing if a genetic test can identify men with advanced prostate cancer who might benefit most from a specific chemotherapy drug called carboplatin. It involves men whose cancer has spread and stopped responding to standard hormone therapies. The goal is to see if …

This early-stage trial is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have stopped responding to standard treatments. The study is focusing on specific cancers, including certain types of lung, ovarian, and pancreatic …

This study is for postmenopausal women with early-stage, hormone-sensitive breast cancer who have a high risk of the cancer returning. It aims to see if adding a new drug called abemaciclib to standard hormone therapy is better at preventing cancer recurrence than hormone therapy…

This study is testing whether a genetic score from a saliva test can help doctors decide which men should be screened for prostate cancer. It enrolled 329 men aged 55-69 to see if those with the highest genetic risk scores are more likely to have cancer found on a biopsy. The goa…

This study aims to find inherited genetic changes that increase a man's risk of developing prostate cancer. Researchers are collecting blood samples and family history information from over 23,000 men, focusing on those diagnosed at a younger age or with a family history of the d…

This study aims to understand if annual PSA blood tests can help find prostate cancer earlier in men who carry high-risk BRCA or Lynch syndrome gene mutations. It will compare about 850 men with these mutations to 850 similar men without them over five years. The goal is to learn…